Sitryx

We recently held our annual Sitryx company away day in Oxford. This was a fantastic opportunity to come together as a team, reflect on our achievements, and celebrate the significant progress across our five programmes.   We enjoyed a varied and engaging program of activities, including an interview with an atopic dermatitis patient. In this session our CEO, Iain Kilty, and Chief Medical Officer, Ravi Rao, underscored the pressing unmet need in atopic dermatitis and the importance of developing innovative therapies for patients who continue to struggle with this disease.   We also focused on what makes the Sitryx story so unique and an amazing place to work, namely the groundbreaking science at the heart of our mission and the exceptional team driving it forward. To round the day off, we took some time to unwind with a creative painting session led by Ed Sumner, followed by our annual Sitryx quiz hosted by our very own Quizmaster, Matt Kelly!   More than just a day away from the lab, this was a powerful reminder of why we do what we do – pushing the boundaries of medical innovation to make a real difference to patients' lives. Huge thanks TeamSitryx for making this a great day!   #ExceptionalPeople #InspiringExcellence #PioneeringScience #PrecisionImmunology #DrugDiscovery #DrugDevelopment 

A big thank you to PwC UK for hosting another thought-provoking Life Sciences webcast yesterday, delving into key topics in our sector such as #GenAI, successful partnerships with Big Pharma and much more. This marks the end of a rewarding few days at #LondonLifeSciencesWeek, reconnecting with friends and colleagues but also making promising new connections with companies and investors at Jefferies London Healthcare conference.   #BiotechCommunity #Innovation #Partnerships #Immunology #DrugDevelopment 

Check out a recent In Vivo article by David Wild exploring ‘The Future of Inflammation: The Inflammasome and Beyond’ featuring Sitryx CEO Iain Kilty. Iain discusses our innovative immunometabolism approach that targets cellular metabolic pathways to reset immune responses.   The article highlights emerging strategies to manage inflammation beyond traditional methods. Sitryx’s unique approach, validated by our global licensing and research collaboration with Eli Lilly, has already yielded promising developments, including our lead asset SYX-5219 for atopic dermatitis, expected to enter the clinic in early 2025.   This is another excellent read from In Vivo - full article here: https://lnkd.in/eE_i2Tte   #Biotech #Immunology #PrecisionImmunology #DrugDiscovery #DrugDevelopment #Biotechnology Citeline Commercial

Our Chief Executive Officer, Iain Kilty, will be joining leading global, public and private companies from the pharmaceutical, biotechnology, medical technology and healthcare services sector at the Jefferies London Healthcare Conference 2024 taking place next week, 19-21 November.   We’re looking forward to connecting with leading executives to discuss near- and long-term investment opportunities within the immunology sector, the current trends driving healthcare in the U.S. and internationally, as well as our latest research in immuno-metabolism targeting therapies for chronic autoimmune and inflammatory diseases.   If you would like to connect with the team in London, please do get in touch by emailing us at [email protected]   #JefferiesHealthcare #Biotech #Immunology #PrecisionImmunology #DrugDiscovery #DrugDevelopment #Biotechnology 

Another great BIO-Europe meeting this year in Stockholm, where our President Neil Weir, Principal Scientist Ryan Kyle, and Chief Business Officer Carrie Cook, were profiling our advancements in immunometabolism-targeting therapies for chronic autoimmune and inflammatory diseases.   Thank you to the industry leaders and potential partners and investors, who spent time with us to learn more about Sitryx — we are excited to explore the potential collaborative opportunities that emerged and look forward to continuing these important conversations as we advance a new generation of therapies for patients.   #BIOEurope2024 #Immunometabolism #Biotech #DrugDiscovery #AutoimmuneDiseases #Inflammation

Our CEO, Iain Kilty, recently joined Jim Cornall on Beyond Biotech—the #podcast from Labiotech.eu—to dive into Sitryx’s pioneering work in immunometabolism. From his journey to CEO to Sitryx’s innovative approach to immunometabolism, Iain shares how targeting metabolic pathways have the potential to reset immune responses, moving beyond antibody-based therapies and earlier immunosuppression treatments. By focusing on the specific needs of immune cells, Sitryx is opening new pathways to treat autoimmune and inflammatory diseases and drive sustained disease remission. Don’t miss the #episode: https://lnkd.in/dz4b3Yea #Biotech #Immunology #PrecisionImmunology #DrugDiscovery #DrugDevelopment #Biotechnology

Our President, Neil Weir, Chief Business Officer, Carrie Cook, and Principal Scientist, Ryan Kyle, are heading to Stockholm, Sweden, for the 30th annual BIO-Europe event taking place from 4-6 November.   They’ll be connecting with industry leaders, prospective partners, and investors to discuss our latest research advancing a new generation of therapies for chronic autoimmune and inflammatory diseases, and to explore new opportunities within the immunology sector.   If you would like to connect with the team in Stockholm, please do get in touch via the partneringONE system or by emailing us at [email protected]   Find the full conference agenda here: https://lnkd.in/eXzpc2S2   #Biotech #Immunology #PrecisionImmunology #DrugDiscovery #DrugDevelopment #Biotechnology

Our Chief Medical Officer, Ravi Rao, our VP Clinical Development, Lisa Pierre, and VP Programme Management & Development Operations, Gordon Dingwall were recently in Amsterdam at the 2024 European Academy of Dermatology and Venereology Congress.   This was another insightful event which provided the opportunity to engage in the latest advances in dermatology and to connect with colleagues and leaders in the field.   Find out where the Sitryx team will be next: https://lnkd.in/eZn8GHZd   #Biotech #Immunology #Dermatology #PrecisionImmunology #DrugDiscovery #DrugDevelopment #Biotechnology 

Last week, our Associate Principal Scientist, Angharad Fenton-May, and Scientist, Weronika Samon, were in sunny St. Julians, Malta, for the 3rd Metabolism in Health and Disease Conference.    The meeting gathered researchers from different areas of biology to discuss the impact of metabolism on cell function and the role this plays in immunity, metabolism and cancer, to gain a more integrated understanding of how metabolism impacts health and disease.   Another excellent conference, highlighting the latest developments in the field of immunometabolism, allowing us to ultimately move research in the field forward.   Find out where the Sitryx team will be next: https://lnkd.in/eZn8GHZd   #Biotech #Immunology #PrecisionImmunology #DrugDiscovery #DrugDevelopment #Biotechnology 

Our CEO, Iain Kilty, has been featured on the latest BioBoss #podcast with John Simboli.   With more than 25 years of global biopharmaceutical industry experience, Iain shares insights on his transition from Chief Scientific Officer to Chief Executive Officer of Sitryx, emphasising the importance of leveraging scientific expertise to drive innovative drug development for autoimmune diseases, while navigating the complexities of leadership and decision-making in a biotech environment.     To listen to the full #episode: https://lnkd.in/eZ9TviA8   #Biotech #Immunology #PrecisionImmunology #BioBoss #DrugDiscovery #DrugDevelopment #Biotechnology